MDPV
3,4-methylenedioxypyrovalerone
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDPV (3,4-methylenedioxypyrovalerone) is a synthetic stimulant of the pyrrolidinophenone class. It is roughly ten times more potent than cocaine in animal models.[1] It blocks dopamine and norepinephrine reuptake in the brain, driving intense stimulation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, methylphenidate, alpha-PVP +1 morecocaine, methylphenidate, alpha-PVP, MDPHP show less
MDPV was synthesized in 1969 and patented as a stimulant, but never developed for medical use.[3] By 2010–2012 it was the dominant ingredient in "bath salts" sold at US convenience stores, driving a surge of emergency department visits.[4] International scheduling starting in 2011 pushed it off most markets; structural analogs like alpha-pvp have since replaced it.[3]
Subjective effects include intense euphoria, psychomotor stimulation, wakefulness, heightened motivation, and sharp focused drive. The experience is almost purely dopaminergic — raw stimulant energy without the emotional warmth of substances like MDMA, and the high tips rapidly toward paranoid dysphoria with repeated doses.[5] Compulsive redosing, anxiety, paranoid ideation, and insomnia are characteristic unwanted effects.
MDPV carries extreme abuse liability and high acute toxicity; multiple deaths are confirmed, including one at a blood level far below typical recreational use.[3] Acute psychosis occurs in 26–40% of emergency presentations,[6] and compulsive redosing rapidly escalates into cardiovascular and psychiatric crisis. No human clinical studies have been conducted — what is known comes from animal models, forensic cases, and emergency department reports.
History[edit]
Discovery
MDPV was synthesized at Boehringer Ingelheim in 1969 and patented as a central nervous system stimulant.[3] It was designed as a modification of pyrovalerone, with the methyl group on the aromatic ring replaced by a methylenedioxy moiety.[7] Despite showing stimulant activity, it was never taken into clinical trials and remained an obscure patent entry for over three decades.
Emergence and the bath salts crisis
MDPV appeared in online drug communities around 2004–2005 and entered European illicit markets by 2006.[3] Between 2010 and 2012, products labeled "bath salts" or "plant food" containing MDPV flooded US convenience stores and head shops, triggering an explosion of emergency department visits.[8][9] MDPV was identified as the dominant psychoactive ingredient in the majority of analyzed bath salts products during this period.
Scheduling and decline
The US Drug Enforcement Administration placed MDPV in Schedule I via emergency order in October 2011, alongside mephedrone and methylone.[10] The UK had classified it as Class B in July 2010, and most EU states followed after a 2013 EMCDDA-Europol risk assessment.[11] Following scheduling, MDPV was largely replaced on recreational markets by analogs like alpha-pvp and MDPHP.[3]
The name "bath salts" was a marketing label, not a description — products were sold in small packets labeled "not for human consumption" to circumvent drug laws. The term became a media shorthand for synthetic cathinone intoxication during 2011–2012, often accompanied by sensationalized reports of extreme behavior. MDPV itself has no widely established street name distinct from the bath salts branding; in drug communities it is typically referred to by its abbreviation.
Chemistry[edit]
Structural class
MDPV belongs to the α-pyrrolidinophenone class of synthetic cathinones. It is closely based on pyrovalerone, differing by one structural change: the methyl group on the aromatic ring is replaced by a 3,4-methylenedioxy group — the same modification found in MDMA.[7] Its molecular formula is C₁₆H₂₁NO₃ (molecular weight 275.34 g/mol).
The pyrrolidine ring at its core is too bulky to pass through the DAT's pore — this is why MDPV blocks reuptake rather than triggering dopamine release.[1][2] It crosses into the brain more readily than most cathinones, contributing to its rapid onset and high potency.[2]
Pharmacology[edit]
Mechanism of action
MDPV blocks the dopamine and norepinephrine transporters with over 800-fold selectivity for dopamine over serotonin.[1] Unlike mephedrone and methylone, which force monoamine release, MDPV works only as a reuptake blocker.[1][2][12] In animal models it is at least ten times more potent than cocaine at raising dopamine in the brain's reward circuits.[1]
Pharmacokinetics
No human pharmacokinetic data exist. In rats, MDPV reaches peak blood levels within 13–19 minutes and peak brain concentrations within 30 minutes.[13][14] It accumulates in the brain at roughly twice the blood concentration, with a plasma half-life of approximately 80 minutes.[14] MDPV itself — not its breakdown products — drives the behavioral effects.[13][15]
Metabolism
MDPV is broken down in the liver by cytochrome P450 enzymes.[16][15] The main breakdown product retains some dopamine-blocking activity but penetrates the brain poorly, contributing minimally to stimulant effects.[13][15] No drug-drug interaction studies have been published.
Neuroscience[edit]
Where it acts
MDPV's defining neural action is intense dopamine accumulation in the mesolimbic mesolimbic pathway — the circuit connecting the brain's reward center to the nucleus accumbens that drives motivation and wanting.[1][5][17] This reward activation exceeds that produced by mephedrone or methylone at equivalent doses.
Why it matters
MDPV's extreme dopamine selectivity massively amplifies wanting — the compulsive drive to seek more — while only modestly affecting actual pleasure.[18] This is why redosing becomes compulsive even as the high diminishes: the urge to take more intensifies while the reward shrinks.
A single exposure produces measurable brain connectivity changes that persist at least 24 hours.[19] Tolerance builds quickly through transporter internalization,[20] while repeated exposure is expected to produce sensitization — progressively stronger compulsive drive — through lasting changes in reward circuitry.
No human brain imaging studies of MDPV have been performed. Whether MDPV causes direct damage to dopamine neurons — as methamphetamine does — is unknown; its reuptake-blocker mechanism theoretically limits this risk, but no studies have tested this.
Subjective Effects[edit]
MDPV produces almost pure dopaminergic stimulation — intense drive, focused energy, and a relentless sense of momentum. There is no empathogenic warmth. The high shifts quickly toward paranoia and agitation with repeated doses, more abruptly than with most stimulants.[5]
Pharmacologically, MDPV sits closest to alpha-pvp — identical mechanism, similar potency. Its binge-driving profile resembles crack cocaine more than oral amphetamine or methylphenidate. Where mephedrone and methylone blend stimulation with warmth, MDPV delivers stimulation alone.
Effect Grid
At common doses (8–14 mg oral), the full MDPV stimulant experience manifests: pronounced euphoria, strong psychomotor stimulation, intense focus and motivation, thought acceleration, wakefulness, and markedly increased energy. Sexual arousal enhancement is frequently reported. Confidence and talkativeness increase substantially.
Physically, tachycardia, elevated blood pressure, diaphoresis (sweating), jaw clenching, and appetite suppression are typical. Body temperature rises and thirst increases. Vasoconstriction may cause cold extremities and difficulty urinating.
Compulsive redosing urges become significant at this range. Sleep is impossible for 4–8 hours. The crash following the acute phase may involve dysphoria, fatigue, and irritability lasting hours to days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Gustatory hallucination
Restlessness · Pupil dilation · Dry mouth · Heart rate perception changes · Insomnia · Physical fatigue · Respiratory stimulation · Muscle tension · Excessive sweating · Dehydration sensation · Nausea · Temperature dysregulation · Trembling · Involuntary body movements · Headache · Motor control impairment · Sexual arousal enhancement · Diarrhea · Seizure threshold reduction · Vomiting · Tactile hallucination
Heart rate perception changes · Insomnia · Physical fatigue · Respiratory stimulation · Muscle tension · Excessive sweating · Dehydration sensation · Nausea · Trembling · Involuntary body movements · Headache · Motor control impairment · Sexual arousal enhancement · Diarrhea · Seizure threshold reduction · Vomiting · Tactile hallucination
Cognitive dysphoria · Confusion · Thought disorganization · Thought loops · Motivation enhancement · Motivation suppression · Creativity enhancement · Focus enhancement · Thought deceleration · Thought organization · Delusions · Delirium
Thought loops · Motivation enhancement · Motivation suppression · Creativity enhancement · Focus enhancement · Thought deceleration · Thought organization · Delirium
Anhedonia · Dysphoria · Emotional lability · Mania · Empathy enhancement
Empathy enhancement
Social disconnection · Derealization
Timeline
First alerts emerge 15–30 minutes after oral ingestion: a subtle shift in alertness, mild mood brightening, and faint increase in heart rate. Effects may be overlooked at threshold doses.
Stimulation builds noticeably over 15–30 minutes. Euphoria, energy, and focus increase in tandem with rising heart rate and body temperature. Appetite suppression becomes definite.
Maximum stimulation sustained for 1–2 hours. Intense euphoria, psychomotor drive, thought acceleration, and heightened motivation dominate. Cardiovascular effects are at their strongest.
Stimulation remains elevated but euphoria diminishes. Residual focus and wakefulness persist. Anxiety, jaw tension, and restlessness may become more prominent as the hedonic component fades.
Effects gradually decline over 1–1. 5 hours. Residual stimulation, mild dysphoria, and physical tension persist.
Aftereffects range from mild residual stimulation to pronounced dysphoria, fatigue, irritability, and depressed mood. Duration varies enormously — from 2 hours at low doses to 48 hours following heavy use or binges. Sleep quality may remain impaired.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · methylphenidate · alpha-PVP
Toxicity
Acute toxicity
MDPV produces a severe stimulant toxicity pattern at recreational doses. Rapid heart rate occurs in 63% of emergency visits,[8] high blood pressure in 25%,[6] alongside extreme agitation,[4] dangerously elevated body temperature, and heavy sweating.[21][14]
Severe cases involve muscle breakdown, acute kidney failure, liver damage, and multi-organ failure.[21][22] Seizures, stroke, heart attack, and cardiorespiratory collapse are documented.[4] Extreme agitation combined with overheating and cardiovascular instability — a state sometimes called excited delirium — carries significant death risk.[4][3] Intravenous use is associated with the most dangerous presentations.[21]
MDPV is not detected by standard urine drug tests. A person can present with severe stimulant toxicity and test negative on routine screens. Laboratory confirmation requires specialized mass spectrometry testing.[4][22]
Fatalities
Multiple deaths from MDPV are confirmed in the medical literature. Blood concentrations in fatal cases have ranged from 39 ng/mL to over 400 ng/mL,[23][24] but one death occurred at only 6 ng/mL — far below typical recreational concentrations — via overheating and cardiac arrest.[3]
No lethal dose has been established in humans or controlled animal studies. Death can occur through indirect mechanisms — catecholamine surge, overheating, excited delirium — at concentrations far below those associated with typical use.
Heart toxicity
In laboratory models, MDPV directly disrupts cardiac electrical activity at high concentrations, slowing heart rate and interfering with conduction.[25] This cardiac effect operates independently of the stimulant effects on the nervous system.[25]
Psychological Risks
MDPV-induced psychosis is a well-documented clinical risk. Paranoid delusions and hallucinations occur in 26–40% of emergency presentations,[6][8] and the presentation can be indistinguishable from acute schizophrenia.[4] The 26–40% rate is notably high compared to other stimulants, reflecting MDPV's extreme dopaminergic potency.
Psychosis can persist after stopping MDPV, with cases requiring electroconvulsive therapy for resolution.[26] Repeated use is linked to lasting psychiatric effects including paranoid ideation and persistent delusions.[27] Self-harm and suicidal ideation are documented in clinical presentations.[4]
Tolerance & Dependence
Tolerance builds rapidly within a session as dopamine transporters are pulled off cell surfaces, driving dose escalation and binge patterns.[20][19] Animal studies consistently show extreme abuse potential: rats self-administer MDPV at all doses tested and escalate intake at rates comparable to methamphetamine.[5][18] MDPV addiction has been confirmed in human injection drug users.[28]
Brain changes persist for at least 24 hours after a single exposure.[19] No formal withdrawal profile exists — by analogy with cocaine, a crash of low mood, anhedonia, fatigue, and excessive sleep is expected. Cross-tolerance with Cocaine, methylphenidate, and alpha-pvp is expected based on shared mechanism.
Drug Interactions
Stimulant combinations
Combining MDPV with other stimulants (Cocaine, amphetamines, caffeine) amplifies cardiovascular toxicity through additive catecholamine elevation. MDPV and caffeine together produce reinforcement greater than predicted by simple addition,[29] and cardiovascular effects of MDPV-methylone-caffeine mixtures have been directly studied in animals.[30]
Serotonergic combinations
MDPV's negligible serotonin activity makes serotonin syndrome unlikely when MDPV is the only agent involved. Combinations with MDMA or tramadol carry cardiovascular risk from combined stimulant effects.inferred Tramadol also lowers seizure threshold, compounding MDPV's own documented seizure risk.[4]
Metabolic interactions
MDPV is metabolized by liver enzymes (CYP2C19, CYP2D6, CYP1A2).[16] Drugs that inhibit these enzymes may raise MDPV blood levels and increase toxicity. No specific interaction studies have been published.
Alcohol
No MDPV-specific alcohol data exist. General concerns include masking of cardiovascular distress, impaired temperature regulation, and additive dehydration.
Contraindications
No MDPV-specific contraindication studies exist. The following are based on MDPV's pharmacological profile and documented clinical toxicity:
Absolute:
- Heart conditions — MDPV's potent stimulant effects (rapid heart rate in 63% of presentations, high blood pressure in 25%) and documented heart attacks make any cardiovascular compromise a high-risk setting[4]
- Psychotic disorders — MDPV induces acute psychosis in 26–40% of emergency cases and can trigger persistent psychotic states[6][26]
- Concurrent stimulant use — additive or synergistic cardiovascular toxicity is documented[29][30]
Relative:
- Bipolar disorder — manic episodes documented with cathinone use[27]
- Kidney impairment — MDPV causes acute kidney failure through multiple mechanisms[21][22]
- Liver impairment — liver damage documented; impaired drug clearance expected[21]
- Seizure disorders — seizures documented[4]
- Pregnancy — no safety data; potent stimulant effects present obvious fetal risksinferred
Harm Reduction[edit]
Forms & Identification
MDPV has been sold as crystalline powder ranging from white to off-white when pure, to grey, brown, or yellow-green when impure. During the bath salts era it was commonly mixed with other cathinones or sold unlabeled, making identification by appearance unreliable.
Standard immunoassay drug tests do not detect MDPV — only mass spectrometry can confirm its presence. Reagent testing can narrow identification but cannot reliably distinguish MDPV from closely related compounds like alpha-pvp or MDPHP.
Guidelines
- Test material with reagent kits before use; confirm identity through analytical services if possible
- Start with the lowest possible dose — MDPV is active at single-milligram quantities and potency varies by batch
- Use a precision milligram scale; volumetric dosing errors with a substance this potent are dangerous
- Set a firm dose limit before the session begins and do not redose — compulsive redosing is the defining risk pattern with MDPV
- Have a sober companion present who understands the drug's profile and the signs of psychiatric deterioration
- Keep ambient temperature comfortable and hydrate steadily but not excessively
- Avoid physical exertion during the experience
- Oral administration produces the most gradual onset and longest duration; insufflation and injection dramatically increase compulsive redosing risk and acute toxicity
Set & Setting
MDPV's dopaminergic dominance makes set and setting less protective than with serotonergic substances — the core stimulant drive is highly reproducible regardless of environment. A calm, controlled setting with trusted companions reduces the risk of paranoid escalation but does not eliminate it.
Avoid situations requiring sustained social performance or physical exertion. Both amplify cardiovascular strain and hyperthermia risk, and physical activity combined with MDPV's stimulant effects significantly worsens the acute toxicity profile.
Aftercare & integration. The MDPV comedown is characteristically harsh — expect low mood, fatigue, irritability, and difficulty concentrating for 24–72 hours after use. Sleep is the single most restorative intervention; if insomnia persists, avoid further stimulant use including caffeine and maintain a dark, quiet environment.
Eat regular meals even if appetite is suppressed — the body needs caloric and electrolyte restoration after intense sympathomimetic stress. If paranoid ideation or perceptual disturbances persist beyond 48 hours after last use, seek professional evaluation — persistent MDPV psychosis is documented and may require psychiatric treatment.[26]
Recovery & Support
MDPV addiction is a documented clinical entity.[28] The compulsive redosing pattern that defines MDPV use can escalate rapidly into daily use and binge cycles. If use has become difficult to control or is causing harm to health, relationships, or functioning, professional support is warranted.
No MDPV-specific treatment protocols exist. Treatment approaches for cocaine and methamphetamine dependence — behavioral therapy, contingency management, and structured support — are the closest clinical analogues. SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure activity, body temperature hot to the touch through clothing, loss of consciousness, uncontrollable agitation, or any sign of psychotic break (paranoid delusions, hallucinations, violent behavior) all require immediate help.
Immediate steps:
- Call emergency services immediately — do not wait to see if symptoms resolve
- Keep the person in a cool environment; apply cool water to skin if overheating
- Do not attempt to physically restrain unless there is immediate danger of self-harm — restraint can worsen overheating and agitation
- If the person is unconscious, place in the recovery position and monitor breathing
- Remove objects that could cause injury
What to tell the dispatcher: Name the substance (MDPV or synthetic cathinone/bath salts), approximate amount and time of use, and current symptoms — especially body temperature, heart rate, and mental state. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
No reversal agent exists for MDPV overdose. Hospital treatment is supportive: sedation for agitation, cooling for overheating, and monitoring of heart, kidney, and liver function.[31]
Legal Status[edit]
MDPV is controlled in most major jurisdictions worldwide, with emergency scheduling in the US and UK triggering rapid international controls following the 2010–2012 bath salts crisis.[10][11]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduling October 2011; permanent Schedule I 2012[10] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Classified July 2010citation needed |
| Canada | Schedule I (CDSA) | Controlled since September 26, 2012citation needed |
| Australia (WA) | Schedule 9 (Poisons Act 1964) | Prohibited since February 11, 2012citation needed |
| Australia (NSW) | Schedule 9 (SUSP) | Prohibited since September 2013citation needed |
| European Union | Controlled in most member states | EMCDDA-Europol joint report December 2013; risk assessment led to member state scheduling[11] |
Legal status varies by jurisdiction and changes over time. This information is not legal advice — verify current status for your jurisdiction independently.
references
- [1] ^abcdefBaumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products — Neuropsychopharmacology doi:10.1038/npp.2012.204
- [2] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3]
- [4]
- [5] ^abcdWatterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) — Addiction Biology doi:10.1111/j.1369-1600.2012.00474.x
- [6] ^abcdMurphy CM, Dulaney AR, Beuhler MC, Kacinko S (2013) 'Bath salts' and 'plant food' products: the experience of one regional US poison center — Journal of Medical Toxicology doi:10.1007/s13181-012-0243-1